PDF

摘要/Abstract

摘要：

背景与目的： 胃癌作为常见恶性肿瘤之一，早期诊断和治疗对改善患者预后至关重要。本研究基于早期胃癌患者的血清定量蛋白质组学研究，旨在发现潜在诊断早期胃癌的生物标志物。方法： 收集2023年6月—12月在兰州大学第二医院就诊的原发性胃癌患者血清的临床资料与体检的健康对照人群的血清资料。所有资料根据本研究的纳入和排除标准进行筛选。使用数据依赖性的采集模式（data-dependent acquisition，DDA）建立蛋白质谱图库后，数据非依赖性的扫描模式（data-independent acquisition，DIA）对各样本进行单独分析。通过STRING数据库分析蛋白组学中胃癌血清中表达上调的蛋白质相互作用，采用KEGG与基因本体GO数据库分析蛋白质对应基因的信号转导通路与功能注释。通过GEPIA2分析基因在胃癌与非胃癌组织中的表达水平，Kaplan-Meier Plotter分析各基因对应胃癌患者的总生存期。利用定量反转录聚合酶链反应（quantitative reverse transcription polymerase chain reaction，qRT-PCR）法验证差异基因在临床胃癌及癌旁组织中的表达。本研究获得兰州大学第二医院研究伦理委员会的批准（伦理批号：2023A-459）并豁免知情同意。结果： 最终入组并获得30例原发性胃癌患者血清与29例健康对照人群血清资料，另获得8例癌旁组织资料。采用血清定量蛋白质组学共鉴定到666种交集蛋白，其中在胃癌组中有16种蛋白质对应基因表达上调，22种表达下调（P<0.05，|FC|≥1.5）。STRING数据库分析显示，10种上调蛋白质处于互作网络中，KEGG与GO分析表明基因与癌症发生、发展的生物过程密切相关。GEPIA 2与Kaplan-Meier Plotter分析显示B2M、TAGLN2、CTSD、HSP90AB1、SH3BGRL3与CFL1共计6个基因在胃癌组中高表达（P<0.05）且预后不良。qRT-PCR结果表明，TAGLN2、CTSD、SH3BGRL3、CFL1与HSP90AB1在胃癌组织中高表达（P <0.05）。结论： TAGLN2、CTSD、SH3BGRL3、CFL1与HSP90AB1具有作为诊断早期胃癌的血清生物标志物的潜力，有利于胃癌的早诊早治。

关键词: 蛋白质组学, 胃癌, 生物标志物, 早期诊断

Abstract:

Background and purpose: Gastric cancer, as one of the most common malignant tumors, requires early diagnosis and treatment to improve patient prognosis. This study, based on serum quantitative proteomics research of early-stage gastric cancer patients and non-gastric cancer patients, aims to identify potential diagnostic biomarkers for early gastric cancer. Methods: Serum samples from primary gastric cancer patients and healthy control individuals were collected from Lanzhou University Second Hospital between June and December 2023, following inclusion and exclusion criteria. A protein spectral library was established using Data-Dependent Acquisition (DDA) mode, and each sample was analyzed using Data-Independent Acquisition (DIA) mode. The STRING database was used to analyze protein-protein interactions of upregulated proteins in gastric cancer serum. Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) were used to analyze the pathways and functional annotations of the corresponding genes. Gene expression levels in gastric cancer and non-gastric cancer tissues were analyzed using GEPIA 2, and overall survival of each gene in gastric cancer was analyzed using Kaplan-Meier Plotter. Differential gene expression in clinical gastric cancer and adjacent tissues was validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) This study was approved by the Ethics Committee of Lanzhou University Second Hospital (Ethical No.: 2023A-459) and was exempt from the informed consent. Results: Finally, serum samples from 30 primary gastric cancer patients, 29 healthy control individuals, along with the para-cancerous tissues from 8 patients were collected. A total of 666 intersecting proteins were identified through serum quantitative proteomics. Among them, 16 proteins showed upregulated expression and 22 proteins showed downregulated expression in the gastric cancer group (P<0.05, |FC|≥1.5). STRING database analysis showed that 10 upregulated proteins were involved in interaction networks. KEGG and GO analysis indicated that these genes were closely related to the biological processes of cancer occurrence and development. GEPIA 2 and Kaplan-Meier Plotter analysis showed that 6 genes, B2M, TAGLN2, CTSD, HSP90AB1, SH3BGRL3, and CFL1, which were highly expressed in the gastric cancer group (P<0.05) and associated with poor prognosis. Clinical verification by qRT-PCR confirmed that TAGLN2, CTSD, SH3BGRL3, CFL1 and HSP90AB1 were highly expressed in gastric cancer tissues (P<0.05). Conclusion: TAGLN2, CTSD, SH3BGRL3, CFL1, and HSP90AB1 have the potential to serve as clinical early gastric cancer diagnostic serum biomarkers, which may facilitate early diagnosis and treatment of gastric cancer.

Key words: Proteomics, Gastric cancer, Biomarkers, Early diagnosis

中图分类号:

R735.2

杜可为, 张尚弟, 胡文飞, 高山, 甘建新, 尤崇革. 基于血清蛋白质组学的TAGLN2、CTSD等5种早期胃癌生物标志物的发现及初步验证[J]. 中国癌症杂志, 2025, 35(6): 543-554.

DU Kewei, ZHANG Shangdi, HU Wenfei, GAO Shan, GAN Jianxin, YOU Chongge. Discovery and preliminary validation of five early gastric cancer biomarkers, including TAGLN2 and CTSD, based on serum proteomics[J]. China Oncology, 2025, 35(6): 543-554.

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: https://www.china-oncology.com/CN/10.19401/j.cnki.1007-3639.2025.06.003

https://www.china-oncology.com/CN/Y2025/V35/I6/543

[1]	彭东阁, 万子叶, 卢宁. 人工智能在胃癌诊疗和患者预后预测中的应用现状及未来展望[J]. 中国癌症杂志, 2025, 35(5): 496-504.
[2]	卢愚风, 王晗, 谢亦璠, 江一舟, 邵志敏. 中国乳腺癌重要基础转化研究——进展与展望[J]. 中国癌症杂志, 2025, 35(2): 143-153.
[3]	蓝煜, 王风华. 2024晚期胃癌诊疗指南更新对比与梳理：CSCO、NCCN和ESMO[J]. 中国癌症杂志, 2025, 35(2): 219-227.
[4]	葛祖荫, 宋坤, 林云霄, 钟烨凌, 郝敬铎. 循环肿瘤细胞FCGBP和BIGH3作为结直肠癌潜在生物标志物的可行性研究[J]. 中国癌症杂志, 2024, 34(8): 745-752.
[5]	刘帅, 张凯, 张晓青, 栾巍. 派安普利单抗联合安罗替尼和化疗围手术期治疗局部进展期胃癌的探索性研究[J]. 中国癌症杂志, 2024, 34(7): 659-668.
[6]	汪斐, 刘佩, 胡楠. 贝伐珠单抗辅助PD-1抑制剂治疗胃癌对血清miR-20a-5p和miR-515-3p的影响研究[J]. 中国癌症杂志, 2024, 34(5): 493-500.
[7]	上海市抗癌协会胃癌专业委员会, 中国人体健康科技促进会胃肠肿瘤专业委员会. 侵犯邻近脏器的进展期胃癌的临床诊疗中国专家共识（2024年版）[J]. 中国癌症杂志, 2024, 34(5): 517-526.
[8]	许永虎, 徐大志. 21世纪以来胃癌治疗进展及未来展望[J]. 中国癌症杂志, 2024, 34(3): 239-249.
[9]	汪学非, 周鹏, 唐兆庆. 胃癌外科治疗的新进展及发展趋势[J]. 中国癌症杂志, 2024, 34(3): 250-258.
[10]	薛驰, 高鹏, 朱志, 王振宁. 免疫治疗在胃癌的围手术期及转化治疗中的应用和挑战[J]. 中国癌症杂志, 2024, 34(3): 259-267.
[11]	沈洁, 王江立, 王泽洲, 莫淼, 周昌明, 袁晶, 徐大志, 郑莹. 以大型单中心医院登记为基础的6 737例接受手术切除的胃癌患者的生存报告[J]. 中国癌症杂志, 2024, 34(3): 268-277.
[12]	李晶, 郑磊, 高钰. 曲妥珠单抗辅助改良DOF双周方案对顺铂耐药的胃癌患者血清肿瘤标志物及生存率的影响分析[J]. 中国癌症杂志, 2024, 34(3): 286-292.
[13]	冯惠枝, 柳婧美, 卜晓倩. 帕博利珠单抗联合XELOX方案治疗晚期胃癌的回顾性研究[J]. 中国癌症杂志, 2024, 34(11): 1028-1035.
[14]	孙洋, 王炼, 赵萌, 张小凤, 耿志军, 王月月, 宋雪, 左芦根, 李静, 胡建国. 胃癌中FKBP1A高表达的预后价值及其靶向PI3K/AKT对糖代谢的调控作用[J]. 中国癌症杂志, 2023, 33(8): 726-739.
[15]	孙崇源, 赵东兵. 循环肿瘤DNA在胃癌诊疗中的应用进展和展望[J]. 中国癌症杂志, 2023, 33(8): 782-789.

基于血清蛋白质组学的TAGLN2、CTSD等5种早期胃癌生物标志物的发现及初步验证

PDF

摘要/Abstract

引用本文

使用本文

相关文章